These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
170 related items for PubMed ID: 38997625
1. Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory. Ghafoori F, Mokhtari-Azad T, Foroushani AR, Farahmand M, Shadab A, Salimi V. BMC Infect Dis; 2024 Jul 12; 24(1):696. PubMed ID: 38997625 [Abstract] [Full Text] [Related]
5. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy. Madi N, Altawalah H, Alfouzan W, Al-Nakib W, Al-Roumi E, Jeragh A. J Med Virol; 2020 Aug 12; 92(8):963-970. PubMed ID: 31919861 [Abstract] [Full Text] [Related]
6. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel. Levine H, Zarka S, Ankol OE, Rozhavski V, Davidovitch N, Aboudy Y, Balicer RD. Hum Vaccin Immunother; 2015 Aug 12; 11(6):1400-5. PubMed ID: 25891446 [Abstract] [Full Text] [Related]
8. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study]. He HQ, Li Q, Yan R, Zhou Y, Tang XW, Deng X, Xie SY, Chen ZP. Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr 06; 51(4):336-340. PubMed ID: 28395468 [Abstract] [Full Text] [Related]
10. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination. Mahamud A, Masunu-Faleafaga Y, Walls L, Williams N, Garcia P, Teshale E, Williams R, Dulski T, Bellini WJ, Kutty PK. Vaccine; 2013 Aug 12; 31(36):3683-7. PubMed ID: 23770334 [Abstract] [Full Text] [Related]
15. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy. Sultana R, Rahman MM, Hassan Z, Hassan MS. Scand J Immunol; 2006 Dec 12; 64(6):684-9. PubMed ID: 17083626 [Abstract] [Full Text] [Related]
18. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes. Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H. J Trop Pediatr; 2011 Oct 12; 57(5):347-51. PubMed ID: 21078605 [Abstract] [Full Text] [Related]
19. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India. Gupta M, Tripathy JP, Verma M, Singh MP, Kaur R, Ratho RK, Kumar R. Indian J Med Res; 2019 Mar 12; 149(3):396-403. PubMed ID: 31249206 [Abstract] [Full Text] [Related]
20. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand. Chaiwarith R, Praparattanapan J, Nuket K, Kotarathitithum W, Supparatpinyo K. BMC Infect Dis; 2016 Apr 30; 16():190. PubMed ID: 27138005 [Abstract] [Full Text] [Related] Page: [Next] [New Search]